Susquehanna International Group, LLP Revance Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

$641 Billion
Q4 2024

A detailed history of Susquehanna International Group, LLP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 303,073 shares of RVNC stock, worth $778,897. This represents 0.0% of its overall portfolio holdings.

Number of Shares

303,073

Previous 56,631 435.17%

Holding current value

$778,897

Previous $145,000 436.55%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	N/A	246,442 Added 435.17%	303,073 $778,000
Q3 2024 Nov 14, 2024	SELL	$2.57 - $2.57 $309,278 - $309,278	-120,342 Reduced 68.0%	56,631 $145,000
Q2 2024 Aug 15, 2024	BUY	$2.34 - $4.73 $133,529 - $269,912	57,064 Added 47.59%	176,973 $454,000
Q1 2024 May 07, 2024	BUY	$4.65 - $9.31 $408,190 - $817,259	87,783 Added 273.25%	119,909 $589,000
Q4 2023 Feb 14, 2024	SELL	$5.81 - $11.2 $607,383 - $1.17 Million	-104,541 Reduced 76.49%	32,126 $282,000
Q3 2023 Nov 14, 2023	SELL	$11.47 - $25.07 $35,224 - $76,989	-3,071 Reduced 2.2%	136,667 $1.57 Million
Q2 2023 Aug 11, 2023	BUY	$24.7 - $37.61 $2.13 Million - $3.24 Million	86,073 Added 160.39%	139,738 $3.54 Million
Q1 2023 May 16, 2023	SELL	$18.36 - $35.27 $3.81 Million - $7.32 Million	-207,453 Reduced 79.45%	53,665 $1.73 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $2.99 Million - $5 Million	163,037 Added 166.23%	261,118 $4.82 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $529,679 - $1.05 Million	-36,963 Reduced 27.37%	98,081 $2.65 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $142,767 - $252,817	-12,393 Reduced 8.41%	135,044 $1.87 Million
Q1 2022 May 16, 2022	BUY	$12.36 - $20.31 $1.24 Million - $2.03 Million	100,134 Added 211.69%	147,437 $2.88 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $42,177 - $94,339	-3,385 Reduced 6.68%	47,303 $772,000
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $263,445 - $339,372	-10,219 Reduced 16.78%	50,688 $1.41 Million
Q2 2021 Aug 11, 2021	BUY	$26.8 - $31.84 $322,645 - $383,321	12,039 Added 24.64%	60,907 $1.81 Million
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $2.29 Million - $2.85 Million	-95,195 Reduced 66.08%	48,868 $1.37 Million
Q4 2020 Feb 16, 2021	BUY	$23.41 - $28.34 $2.76 Million - $3.34 Million	117,736 Added 447.21%	144,063 $4.08 Million
Q3 2020 Nov 16, 2020	SELL	$23.23 - $34.3 $94,244 - $139,155	-4,057 Reduced 13.35%	26,327 $662,000
Q2 2020 Aug 14, 2020	SELL	$12.6 - $26.55 $1.07 Million - $2.26 Million	-85,097 Reduced 73.69%	30,384 $742,000
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $497,764 - $1.11 Million	39,949 Added 52.89%	115,481 $1.71 Million
Q4 2019 Feb 14, 2020	SELL	$11.66 - $20.15 $231,614 - $400,259	-19,864 Reduced 20.82%	75,532 $1.23 Million
Q3 2019 Nov 14, 2019	BUY	$10.22 - $14.5 $303,891 - $431,157	29,735 Added 45.29%	95,396 $1.24 Million
Q2 2019 Aug 16, 2019	BUY	$10.67 - $15.49 $333,010 - $483,442	31,210 Added 90.59%	65,661 $852,000
Q2 2019 Aug 14, 2019	BUY	$10.67 - $15.49 $216,526 - $314,338	20,293 Added 143.33%	34,451 $447,000
Q3 2018 Nov 14, 2018	SELL	$23.55 - $30.1 $3.91 Million - $5 Million	-165,947 Reduced 92.14%	14,158 $352,000
Q4 2017 Feb 14, 2018	BUY	$24.55 - $36.3 $2.61 Million - $3.86 Million	106,243 Added 143.84%	180,105 $6.44 Million
Q3 2017 Nov 14, 2017	BUY	$22.55 - $28.1 $1.67 Million - $2.08 Million	73,862	73,862 $2.04 Million

Others Institutions Holding RVNC

# of Institutions

208

Shares Held

80.9M

Call Options Held

2.26M

Put Options Held

5.48M

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Revance Therapeutics, Inc. Transaction History